This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
This study included an active control group who received the licensed Priorix (measles, mumps, rubella \[MMR\] vaccine).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Antibody levels after vaccination
Safety of the study vaccines
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Bad Saulgau, Baden-Wurttemberg, Germany
GSK Investigational Site
Bönnigheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Ehingen, Baden-Wurttemberg, Germany
GSK Investigational Site
Kehl, Baden-Wurttemberg, Germany
GSK Investigational Site
Kirchzarten, Baden-Wurttemberg, Germany
GSK Investigational Site
Ludwigsburg, Baden-Wurttemberg, Germany
GSK Investigational Site
Marbach, Baden-Wurttemberg, Germany
GSK Investigational Site
Oberkirch, Baden-Wurttemberg, Germany
...and 38 more locations